Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial. - Catlett, Ian M.; Gao, Lu; Hu, Yanhua; Banerjee, Subhashis; Krueger, James G. (Dermatology & Therapy, 2024)